At a glance
ClinicalIndex Comparison Record- ✓Diagnosed with myelofibrosis with myeloid metaplasia (MMM), agnogenic myeloid metaplasia, post-polycythemic myeloid metaplasia, or post-thrombocythemic myeloid metaplasia, confirmed by central pathology review
- ✓ECOG performance status 0, 1, or 2
- ✓Hemoglobin ≤10 g/dL or transfusion-dependent
- ✓Lenalidomide-naïve (never previously treated with lenalidomide)
- ✕Known hypersensitivity to thalidomide or lenalidomide
- ✕Positive status for HIV or infectious hepatitis type A, B, or C
- ✕Any other active malignancy
- ✕Any condition placing the patient at unacceptable risk or confounding data interpretation, in the physician's opinion
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia
In Brief
A Phase 2 clinical trial evaluating lenalidomide, prednisone, and 1 other intervention for Essential Thrombocythemia and 2 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving lenalidomide together with prednisone works in treating patients with myelofibrosis. Lenalidomide may stop the growth of myelofibrosis by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with prednisone may kill more cancer cells.
Study Details
Timeline
Interventions
Given orally (PO)
Given PO
Correlative studies